Skip to content
Screener

Vaxcyte, Inc. PCVX Financing Cash Flow

Financing Cash Flow at other companies

Pfizer logo
PfizerPFE
-$2.86B+45.4%
Merck & Co. logo
Merck & Co.MRK
-$2.98B+48.2%
Moderna logo
ModernaMRNA
$14M+55.6%
Novavax logo
NovavaxNVAX
$1.2M+215%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
-$10.46M+16.1%
Regenxbio logo
RegenxbioRGNX
$17.57M-87.4%

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$8.07B+89.7%
Enterprise value$7.93B+96.5%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:12 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001649094-26-000017
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from issuance of shares through employee equity incentive plans9,0326,049
Proceeds from issuance of common stock from follow-on offering, net of issuance costs601,846
Taxes paid related to the net share settlement of equity awards(9,295)(5,290)
Net cash provided by financing activities601,583759
Effect of exchange rate changes on cash and cash equivalents(664)1,172
Net increase (decrease) in cash, cash equivalents and restricted cash86,884(41,026)
Cash, cash equivalents and restricted cash, beginning of period175,425389,195
Cash, cash equivalents and restricted cash, end of period$262,309$348,169

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Vaxcyte, Inc.'s financing cash flow?
Vaxcyte, Inc. (PCVX) reported financing cash flow of $601.58M in Q1 2026.
How has Vaxcyte, Inc.'s financing cash flow changed year-over-year?
Vaxcyte, Inc.'s financing cash flow increased by 79159.9% year-over-year, from $759K to $601.58M.
What is the long-term trend for Vaxcyte, Inc.'s financing cash flow?
Over 4 years (2021 to 2025), Vaxcyte, Inc.'s financing cash flow has grown at a -42.0% compound annual growth rate (CAGR), from $17.8M to $2.01M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Vaxcyte, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude